| Objective To investigate the short-term side effects after the medication of zoledronic sodium. Methods One hundred and fifty-six osteoporosis patients from November 2009 to February 2012 were treated with zoledronic sodium. Clinical manifestations were observed in patients within 1 month after the medication, including pain, fever, and other adverse events. One hundred and seven patients with spinal fractures treated with vertebroplasty but without the medication of zoledronic sodium were observed simultaneously. The difference of the incidence of side effects between the two groups was compared. Results All the patients were followed up. The results revealed that in zoledronic sodium group, the incidence of pain and fever was 17.3% and 12.8%, respectively. In control group, the incidence of pain and fever was 1.87% and 0.93%, respectively. The difference between the two groups was significant (P<0.001). In addition, in zoledronic sodium group, one patient with skin allergy and one patient with myocardial ischemia and angina were observed. The situation of one patient with multiple myeloma was aggravated. And one patient had pneumonia and died of respiratory failure. Conclusion The application of zoledronic sodium in osteoporosis patients can cause pain, fever and other side effects, and may even cause skin allergy, angina, exacerbation of multiple myeloma, pneumonia, respiratory failure, and other adverse events. Close supervision after the medication at the same day is recommended, and the follow-up after the medication for the first 2 weeks should be strengthened. |